Simmunome and Mila Announce Partnership to Advance AI in Drug Development

Logos Mila et Simmunome inc.

MONTREAL, November 21, 2023 – Simmunome Inc., a Montreal-based techbio company leveraging generative artificial intelligence (AI) to increase the predictability of clinical drug development announces today its partnership with Mila - Quebec AI Institute, the world’s largest academic deep learning research center. 

Simmunome integrates multi-omic data to generate in silico disease models that accurately capture physiological processes to avoid late-stage failures and increase efficacy in patients. Their unique approach enables explainable predictions on how molecular pathways are linked to clinical outcomes, leveraging machine learning (ML) to create precise, comprehensive disease models that significantly optimize the clinical trial landscape.

Simmunome is committed to providing pharmaceutical companies and academic institutions with access to a robust disease-agnostic platform and a more comprehensive understanding of mechanisms of disease, drug action and novel biomarkers. 

“We are ecstatic to join forces with an esteemed institution like Mila, known for its pioneering work in AI. This collaboration stands as a testament to our shared vision of advancing clinical research and development through innovative AI applications. Through this joint endeavor, we hope to engage in ground-breaking research and make contributions to the field. Our partnership will also grant us access to a vast talent pool comprising some of the most brilliant minds in the industry. Working closely with Mila researchers on joint projects is a key strategy with the potential to allow us to push the boundaries of knowledge and deliver cutting-edge solutions. Together, we aspire to unlock new levels of efficiency and effectiveness in clinical R&D.,” said Nardin Nakhla, PhD, CTO of Simmunome.

“Welcoming Simmunome is a valuable addition to Mila’s community. We believe that AI, especially ML, can have a crucial impact on advancing the development of disease models and innovative medicines. The synergy between Simmunome's clinical insights and Mila's academic expertise shows tremendous potential for achieving significant advancements in patient-centered healthcare,” said Stéphane Létourneau, Executive Vice President of Mila.


About Mila


Founded by Professor Yoshua Bengio of the University of Montreal, Mila is a research institute in artificial intelligence that now brings together over 1,200 specialized researchers in machine learning. Based in Montreal, Mila's mission is to be a global center for scientific advancements that inspire innovation and the growth of AI for the benefit of all. Mila is a globally recognized non-profit organization for its significant contributions to deep learning, especially in the fields of language modeling, automatic translation, object recognition, and generative models. For more information, visit 


About Simmunome


Simmunome is at the leading edge of leveraging AI towards unraveling biological complexity. Simmunome’s platform allows users to input preclinical and clinical data to derive disease-specific insights and help R&D researchers make critical go/no-go decisions. By combining multi-omic data to create comprehensive models of disease, Simmunome simulates biological processes to identify novel drug targets and predict and improve clinical outcomes. Simmunome de-risks clinical research, reduces R&D costs and dramatically accelerates health research and innovation. For more information, visit